Cost–Effectiveness of CYP2B6 Genotyping to Optimize Efavirenz Dosing in HIV Clinical Practice

Bruce R Schackman1 Department of Healthcare Policy & Research, Weill Cornell Medical College, New York, NY, USACorrespondence[email protected]
View further author information

David W Haas2 Department of Medicine, Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, TN, USAView further author information

Sanghee S Park3 Medical Practice Evaluation Center, Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USAView further author information

X Cynthia Li3 Medical Practice Evaluation Center, Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USAView further author information

Kenneth A Freedberg3 Medical Practice Evaluation Center, Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA;4 Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA;5 Department of Health Policy & Management, Harvard TH Chan School of Public Health, Boston, MA, USACorrespondence[email protected]
View further author information

Cost–Effectiveness of CYP2B6 Genotyping to Optimize Efavirenz Dosing in HIV Clinical Practice

Supplemental Document

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Cost–Effectiveness of CYP2B6 Genotyping to Optimize Efavirenz Dosing in HIV Clinical Practice

Supplemental Document

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date